{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.33","upperLimit":"5.3","value":"2.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Patients will be followed for initial response to therapy and for progression of disease. Response criteria will be scored according to International Myeloma Working Group uniform response criteria.","dispersionType":"Full Range","groups":[{"description":"Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.\n\nBortezomib: Given IV\n\nVorinostat: Given PO","id":"OG000","title":"Arm I (Bortezomib and Vorinostat)"}],"paramType":"MEDIAN","populationDescription":"One subject withdrew from the study within first week of study therapy and changed to different therapy and is not included in this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Time to Disease Progression in Patients Who Progressed","type":"SECONDARY","unitOfMeasure":"years"}